Dr. Smith on Acquired Resistance to Targeted Agents for AML

Catherine Smith, MD
Published: Tuesday, Feb 06, 2018



Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).

Over more recent years, more potent and selective inhibitors have been developed such as quizartinib, an active drug that resulted in composite complete remission rates of 40% to 50% in a relapse/refractory FLT3-mutant population. Responses were limited by the rapid development of resistance usually due to on target kinase mutations at the DA35 residue, also found in de novo AML.

Targeted therapies such as gilteritinib have since been developed to target these DA35 mutations. Results from the phase I/II trial resulted in complete remission rates of about 40%. However, the drug is still limited to resistance, and physicians are working to mitigate this resistance in patients.
 


Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).

Over more recent years, more potent and selective inhibitors have been developed such as quizartinib, an active drug that resulted in composite complete remission rates of 40% to 50% in a relapse/refractory FLT3-mutant population. Responses were limited by the rapid development of resistance usually due to on target kinase mutations at the DA35 residue, also found in de novo AML.

Targeted therapies such as gilteritinib have since been developed to target these DA35 mutations. Results from the phase I/II trial resulted in complete remission rates of about 40%. However, the drug is still limited to resistance, and physicians are working to mitigate this resistance in patients.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x